Gene Expression Regulation, Neoplastic
"Gene Expression Regulation, Neoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Descriptor ID |
D015972
|
MeSH Number(s) |
G05.355.315.370
|
Concept/Terms |
Gene Expression Regulation, Neoplastic- Gene Expression Regulation, Neoplastic
- Neoplastic Gene Expression Regulation
- Regulation of Gene Expression, Neoplastic
- Regulation, Gene Expression, Neoplastic
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Neoplastic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Neoplastic".
This graph shows the total number of publications written about "Gene Expression Regulation, Neoplastic" by people in this website by year, and whether "Gene Expression Regulation, Neoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1989 | 0 | 1 | 1 | 1991 | 0 | 2 | 2 | 1992 | 1 | 0 | 1 | 1993 | 0 | 1 | 1 | 1994 | 2 | 0 | 2 | 1995 | 0 | 3 | 3 | 1996 | 0 | 7 | 7 | 1997 | 0 | 4 | 4 | 1998 | 1 | 0 | 1 | 1999 | 3 | 3 | 6 | 2000 | 0 | 1 | 1 | 2001 | 3 | 3 | 6 | 2002 | 2 | 5 | 7 | 2003 | 0 | 2 | 2 | 2004 | 1 | 2 | 3 | 2005 | 5 | 4 | 9 | 2006 | 2 | 5 | 7 | 2007 | 7 | 3 | 10 | 2008 | 3 | 6 | 9 | 2009 | 2 | 4 | 6 | 2010 | 4 | 8 | 12 | 2011 | 3 | 6 | 9 | 2012 | 2 | 13 | 15 | 2013 | 4 | 8 | 12 | 2014 | 10 | 18 | 28 | 2015 | 1 | 6 | 7 | 2016 | 4 | 7 | 11 | 2017 | 4 | 5 | 9 | 2018 | 9 | 11 | 20 | 2019 | 8 | 11 | 19 | 2020 | 3 | 7 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Gene Expression Regulation, Neoplastic" by people in Profiles.
-
Pajovic S, Siddaway R, Bridge T, Sheth J, Rakopoulos P, Kim B, Ryall S, Agnihotri S, Phillips L, Yu M, Li C, Milos S, Patel P, Srikanthan D, Huang A, Hawkins C. Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer. Nat Commun. 2020 12 04; 11(1):6216.
-
Tong J, Krieger JR, Taylor P, Bagshaw R, Kang J, Jeedigunta S, Wybenga-Groot LE, Zhang W, Badr H, Mirhadi S, Pham NA, Coyaud É, Yu M, Li M, Cabanero M, Raught B, Maynes JT, Hawkins C, Tsao MS, Moran MF. Cancer proteome and metabolite changes linked to SHMT2. PLoS One. 2020; 15(9):e0237981.
-
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, Haight J, Tonekaboni SAM, Fortier AM, Kuasne H, McKee TD, Mahmoud H, Kushida M, Cameron S, Dogan-Artun N, Chen W, Nie Y, Zhang LX, Vellanki RN, Zhou S, Prinos P, Wouters BG, Dirks PB, Done SJ, Park M, Cescon DW, Haibe-Kains B, Lupien M, Arrowsmith CH. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat Commun. 2020 08 21; 11(1):4205.
-
Capaci V, Bascetta L, Fantuz M, Beznoussenko GV, Sommaggio R, Cancila V, Bisso A, Campaner E, Mironov AA, Wisniewski JR, Ulloa Severino L, Scaini D, Bossi F, Lees J, Alon N, Brunga L, Malkin D, Piazza S, Collavin L, Rosato A, Bicciato S, Tripodo C, Mantovani F, Del Sal G. Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome. Nat Commun. 2020 08 07; 11(1):3945.
-
Zagozewski J, Shahriary GM, Morrison LC, Saulnier O, Stromecki M, Fresnoza A, Palidwor G, Porter CJ, Forget A, Ayrault O, Hawkins C, Chan JA, Vladoiu MC, Sundaresan L, Arsenio J, Taylor MD, Ramaswamy V, Werbowetski-Ogilvie TE. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat Commun. 2020 07 20; 11(1):3627.
-
Bobyn A, Zarrei M, Zhu Y, Hoffman M, Brenner D, Resnick AC, Scherer SW, Gallo M. Ancestry and frequency of genetic variants in the general population are confounders in the characterization of germline variants linked to cancer. BMC Med Genet. 2020 05 06; 21(1):92.
-
Koneru B, Lopez G, Farooqi A, Conkrite KL, Nguyen TH, Macha SJ, Modi A, Rokita JL, Urias E, Hindle A, Davidson H, Mccoy K, Nance J, Yazdani V, Irwin MS, Yang S, Wheeler DA, Maris JM, Diskin SJ, Reynolds CP. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res. 2020 06 15; 80(12):2663-2675.
-
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin S, Shroff M, Shago M, Hazrati LN, D'Arcy C, Ramaswamy V, Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Ellison DW, Tabori U, Hawkins C. Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell. 2020 04 13; 37(4):569-583.e5.
-
D'Arcy CE, Nobre LF, Arnaldo A, Ramaswamy V, Taylor MD, Naz-Hazrati L, Hawkins CE. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples. J Neuropathol Exp Neurol. 2020 04 01; 79(4):437-447.
-
Saric N, Selby M, Ramaswamy V, Kool M, Stockinger B, Hogstrand C, Williamson D, Marino S, Taylor MD, Clifford SC, Basson MA. The AHR pathway represses TGFß-SMAD3 signalling and has a potent tumour suppressive role in SHH medulloblastoma. Sci Rep. 2020 01 10; 10(1):148.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|